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Summary
 
Apoptotic cells are rapidly engulfed by phagocytes, but the receptors and ligands responsible for
this phenomenon are incompletely characterized. Previously described receptors on blood-
derived macrophages have been characterized in the absence of serum and show a relatively
low uptake of apoptotic cells. Addition of serum to the phagocytosis assays increased the uptake
of apoptotic cells by more than
 
 
 
threefold. The serum factors responsible for enhanced uptake
were identified as complement components that required activation of both the classical path-
way and alternative pathway amplification loop. Exposure of phosphatidylserine on the apop-
totic cell surface was partially responsible for complement activation and resulted in coating the
apoptotic cell surface with C3bi. In the presence of serum, the macrophage receptors for C3bi,
CR3 (CD11b/CD18) and CR4 (CD11c/CD18), were significantly more efficient in the up-
take of apoptotic cells compared with previously described receptors implicated in clearance.
Complement activation is likely to be required for efficient uptake of apoptotic cells within the
systemic circulation, and early component deficiencies could predispose to systemic autoimmu-
nity by enhanced exposure to and/or aberrant deposition of apoptotic cells.
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A
 
lthough the apoptotic cell death program is executed
in hours, the removal of dying cells is normally so
rapid that few cells are seen—even in tissues such as the
thymus, where up to 95% of cells undergo apoptosis (1).
The importance, and complexity, of phagocytosis is high-
lighted by genetic studies of apoptosis in the nematode,
 
Caenorhabditis elegans
 
. Of the 14 genes (CED 1–14) that
regulate apoptosis during development of 
 
C
 
.
 
 elegans
 
, at
least 6 encode proteins that are required for engulfment of
apoptotic cells (2).
An important stage of apoptosis involves the acquisition
of surface changes on the apoptotic cell leading to rapid
recognition and phagocytosis by surrounding cells fol-
lowed by degradation in lysosomes. The mechanisms
whereby apoptotic cells are efficiently identified, removed,
and degraded by phagocytes in mammalian cells are not
well understood. Several ligands and receptors have been
reported to play a role in the initial engulfment of apoptotic
cells in vitro. These include known receptors such as the
 
a
 
v
 
b
 
3
 
 integrin (3), CD36 (4), which share the 
 
a
 
v
 
b
 
3
 
/CD36/
thrombospondin recognition mechanism, other class A and
B scavenger receptors (5–7), the ATP-binding cassette
transporter ABC1 (8), and CD14 (9), as well as unknown
receptors that have been characterized by their lectin bind-
ing properties (10) or by specific recognition of phosphati-
dylserine (PS)
 
1
 
 (11).
In human peripheral blood–derived macrophages, the
known receptors show a relatively low uptake of apoptotic
cells (average of 40 apoptotic cells per 100 macrophages
[12, 13]) and are only partially inhibited by specific block-
ing agents in vitro (3, 9, 14). Significantly, phagocytic as-
says of human monocyte–derived macrophages have been
performed in the absence of serum (3, 9, 11–15). We re-
port that a serum factor(s) provides a more than threefold
increase in the uptake of apoptotic cells by human mac-
rophages and demonstrate that complement components
are required for this high level of uptake.
 
Materials and Methods
 
Phagocytosis Assays.
 
Apoptosis of murine thymocytes was in-
duced by 
 
g
 
-irradiation (600 cGy from a 
 
137
 
Cesium source). The
optimal conditions for thymocyte apoptosis without necrosis
(
 
.
 
60% cells bound annexin V, but 
 
.
 
95% excluded propidium
 
1
 
Abbreviations used in this paper:
 
 CHO, Chinese hamster ovary; HIS, heat-
inactivated serum; NHS, normal human serum; NoS, no serum; PI, pha-
gocytic index; PS, phosphatidylserine.
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iodide and 
 
.
 
98% trypan blue [16]), after irradiation, was culture
for 1 h at 37
 
8
 
C/5% CO
 
2
 
 in RPMI medium without serum. Apop-
tosis of human neutrophils was induced by incubation in me-
dium in the absence of serum at 37
 
8
 
C/5% CO
 
2
 
 for 6 h, condi-
tions during which 
 
.
 
95% of neutrophils do not take up
propidium iodide, and 20–30% are annexin V positive. The Bur-
kitt B cell line, BL-41, and normal human mature peripheral T
cells were rendered apoptotic by 
 
g
 
-irradiation (4,000 cGy) fol-
lowed by incubation in the absence of serum as for human neu-
trophils.
Interaction between human macrophages and apoptotic cells
was performed as described (3, 14) with minor modifications in
the presence or absence of 15% human serum. Human macro-
phages were isolated from peripheral blood monocytes of normal
donors as described (14) and cultured on Chamber-Tek glass
slides (Nunc, Inc., Naperville, IL). 6–7 d after isolation, mac-
rophages were washed three times with serum-free medium. 10
 
6
 
apoptotic cells were offered to 2.5 
 
3 
 
10
 
4
 
 macrophages (approxi-
mate ratio of 40:1) and incubated for 1 h at 37
 
8
 
C/5% CO
 
2
 
. The
interaction was terminated by washing with ice-cold PBS as de-
scribed (3, 14). The slides were fixed with methanol and Wright
stained, and the numbers of apoptotic cells, both surface bound
and internalized, were scored by light microscopy. In each assay,
100–400 macrophages were counted by 2 observers. The phago-
cytic index (PI, number of apoptotic cells bound to or internal-
ized by 100 macrophages) was calculated as described (9, 13).
 
Inhibition Studies.
 
Macrophages were preincubated with the
antibody or tetrapeptide inhibitors for 15 min at 4
 
8
 
C followed by
washing and exposure to autologous apoptotic neutrophils (3,
14). Each experiment was done in triplicate on at least four sepa-
rate occasions. For each blocking experiment, mAbs were used at
a final concentration of 20 
 
m
 
g/ml and the tetrapeptides RGDS
and RGES (Sigma Chemical Co., St. Louis, MO) at a final con-
centration of 2 mM. mAbs were obtained from the following
sources: anti-CR1, 3D9 (R.P. Taylor, University of Virginia,
Charlottesville, VA), anti-CR3 (I domain), MN-41 (V. Vetvicka,
Louisville School of Medicine, Louisville, KY), anti-CR4 (anti-
CD11c; Sigma Chemical Co.), anti-CD36 (FA6; R.L. Sil-
verstein, Cornell Medical College, NY, NY; and IgM; Sigma
Chemical Co.), anti-CD14, 63D3 (American Type Culture Col-
lection, Rockville, MD), and 61D3 (C.D. Gregory, University of
Birmingham, Birmingham, UK).
 
Flow Cytometry.
 
Apoptotic cells were stained with FITC-
conjugated annexin V (Nexins), propidium iodide, and PE-con-
jugated IgG
 
2b
 
k
 
 mouse monoclonal anti–human-iC3b (Quidel,
San Diego, CA). Flow cytometry analysis was performed on a
FACScan
 
Ò
 
 (Becton Dickinson, Mountain View, CA). Mouse
IgG
 
2b
 
k
 
 was used as isotype control for anti-C3bi.
 
Results
 
The Effect of Serum on Uptake of Apoptotic Cells by Human
Macrophages.
 
To determine the effect of serum factors on
the efficiency of phagocytosis of apoptotic cells, the PI was
compared between macrophages exposed to apoptotic cells
in the presence (NHS) or absence (NoS) of normal human
serum as well as in the presence of heat-inactivated serum
(HIS). Since conditions have been established for reliable
induction of apoptosis of murine thymocytes with minimal
necrosis (
 
,
 
5% and 2% uptake of propidium iodide and try-
pan blue, respectively [16]), initial experiments were per-
formed with murine thymocytes. As shown in Fig. 1, 
 
A
 
and 
 
B
 
, heat-labile serum factor(s) induced at least a 10-fold
increase in the PI that was dependent on time, tempera-
ture, and serum concentration. In the presence of 15% se-
rum, at least 5 apoptotic cells were engulfed by most mac-
rophages as shown in Fig. 1 
 
C
 
, whereas 0–1 cells were
macrophage associated in the absence of serum (Fig. 1 
 
D
 
).
Similar results were observed when apoptosis was induced
by dexamethasone (results not shown). The experiments
were then repeated in an entirely autologous system, i.e.,
using serum and macrophages as well as apoptotic neutro-
phils or T cells from the same donor. In the absence of se-
rum, the PI was 37 
 
6 
 
19, similar to previous reports (12,
13), but was 156 
 
6 
 
28 in the presence of serum (represen-
tative examples are shown in Fig. 1, 
 
E
 
–
 
G
 
).
To distinguish between the requirement for serum fac-
tor(s) for opsonization (see below) versus uptake of apop-
totic cells, apoptotic lymphocytes were incubated either
with 15% autologous serum or medium without serum for
1 h at 37
 
8
 
C and the phagocytosis assay was performed in
the absence of serum (two step assay). In the absence of se-
rum at both steps, the baseline PI was 25 
 
6 
 
14 compared
with 81 
 
6 
 
19 when apoptotic lymphocytes had been ex-
posed to serum but the phagocytosis assay performed in the
absence of serum. These findings indicate that serum fac-
tor(s) were more important for opsonization of the apop-
totic cell than at the stage of phagocytosis.
 
Complement Components Are Required for Efficient Uptake of
Apoptotic Cells by Human Macrophages.
 
The marked enhance-
ment of the PI induced by a serum factor that was abrogated
by heating to 56
 
8
 
C for 30 min suggested that complement
components could be responsible for the uptake of apop-
totic cells. To determine whether proteins of the classical
and/or alternative complement pathways were required for
phagocytosis of apoptotic cells, we evaluated the PI in the
presence of serum depleted of specific complement com-
ponents (Fig. 2). When apoptotic neutrophils or T lym-
phocytes were used as targets, normal or C9-deficient se-
rum augmented the PI three- to fivefold. In contrast,
serum depleted of Factor B, C1q, or C3 (not shown) had a
PI only slightly greater than the NoS control. To verify the
specificity of these observations, we performed add-back
experiments with the purified complement components
C1q, Factor B, C3, and C9. As shown in Fig. 2, when
the appropriate complement component was added to the
C1q- or Factor B–deficient serum, the PI returned to the
value observed in the presence of 15% serum. Addition of
C1q in the absence of serum did not restore the PI (data
not shown). Similar results were obtained when murine
thymocytes, Jurkat T cells, or BL-41 B cells were used as
apoptotic targets in these experiments (not shown).
 
PS Exposure Activates Complement.
 
To further investi-
gate the mechanism responsible for complement activation,
we examined whether the major C3 breakdown product,
C3bi, was deposited on the surface of apoptotic neutrophils
or lymphocytes by flow cytometry. As shown in Fig. 3, ap-
optotic lymphocytes (
 
B
 
) and neutrophils (
 
E
 
, 
 
top right
 
) but
not nonapoptotic lymphocytes (
 
A
 
) or neutrophils (
 
D
 
, 
 
bot-
tom left
 
) stained positively for C3bi. Two-color flow cy- 
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tometry (Fig. 3 
 
E
 
) revealed that 31% of the neutrophils
were in the early apoptotic stage (annexin V positive, PI
negative [not shown]; 
 
top 
 
and
 
 bottom right
 
 [17]) and that
C3bi coated 61% of the apoptotic cells and 
 
.
 
90% of the
annexin V
 
high
 
 apoptotic population (Fig. 3 
 
E
 
, 
 
top right
 
). PS
has been shown to serve as a specific ligand for recognition
of apoptotic cells (11). Recognition of PS is particularly
relevant to the engulfment of apoptotic cells, since PS is an
acidic phospholipid that normally resides on the inside of
the cell, but translocates to the outside of the cell membrane
when the cell undergoes apoptosis (18, 19). To determine
whether blocking PS exposure on the apoptotic cells would
inhibit complement activation, we preincubated apoptotic
cells with annexin V, exposed the cells to serum, and then
quantified C3bi exposure by flow cytometry. As shown in
Fig. 3, 
 
C
 
 and 
 
D
 
, annexin V substantially reduced, but did
not completely inhibit, C3bi deposition. These findings
strongly suggest that PS on the surface of apoptotic cells is at
least partially responsible for complement activation.
 
Complement Receptors Are Required for Efficient Uptake of
Opsonized Apoptotic Cells.
 
Human monocytes and mac-
rophages express three known receptors, CR1, CR3, and
CR4, that bind complement proteins or their degradation
products. CR1 (CD35) binds mainly C3b, C4b, and C1q
(20, 21), whereas CR3 (CD11b/CD18) and CR4 (CD11c/
CD18) are relatively specific for C3bi (22). Since apoptotic
cells were coated with C3bi, we performed blocking ex-
periments with mAbs specific to the complement receptors
in order to evaluate their role in ligand binding. As shown
in Fig. 4, mAbs to CR3, CR4, and CR1 inhibited uptake
of apoptotic neutrophils by 60 
 
6 
 
8, 50 
 
6 
 
4, and 11 
 
6 
 
7%,
respectively. Since most prior studies of receptors and
ligands implicated in engulfment of mammalian apoptotic
cells were performed in the absence of serum (3, 9, 11–15),
we evaluated their role in the presence of serum using
mAbs or ligands to inhibit their binding. As shown in Fig.
4 
 
A
 
, all three receptors were highly expressed on the
surface of human monocyte–derived macrophages. Only
Figure 1. Heat-labile serum
factor(s) augment the phagocyto-
sis of apoptotic cells in a concen-
tration-, time-, and temperature-
dependent fashion. (A) Apoptotic
murine thymocytes were offered
to human macrophages in the
presence of 15% normal non–
heat-inactivated human serum
(NHS), 15% normal heat-inacti-
vated (568C for 30 min) serum
(HIS), or without (NoS) the ad-
dition of serum, as described
in Materials and Methods. The
results are expressed as PI, and
the mean 6 SD of five experi-
ments is shown. (B) Phagocyto-
sis of apoptotic cells was com-
pared at 48C and 378C. (C–G)
Wright stain of human macro-
phages after exposure to either mu-
rine apoptotic thymocytes (C and
D) or autologous human apop-
totic neutrophils (E–G) in the
presence (C,  F, and G) or ab-
sence (D and E) of 15% human
serum. Original magnification:
3400. Arrows, some of the apop-
totic cells bound or engulfed.
Figure 2. Both classical and alternative complement components are
required for efficient uptake of apoptotic cells. The efficiency of phago-
cytosis of autologous neutrophils was compared in 15% human serum that
was selectively deficient in the complement components C1q, C3, Factor
B, or C9 (Sigma Chemical Co.). To verify that a specific complement com-
ponent  was responsible for the effect observed, add-back experiments
were performed with the missing factor (C1q, 250 mg/ml; Factor B, 250
mg/ml; or C9, 60 mg/ml [Sigma Chemical Co.]). d, deficient. The mean 6
SD of four experiments is shown. 
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Figure 4. The complement
receptors CR3 and CR4 are pre-
dominantly responsible for up-
take of apoptotic cells in the
presence of serum. (A) The ex-
pression of the complement re-
ceptors was examined on day 7
human macrophages by flow cy-
tometry using specific mouse
mAbs (black histogram) as de-
scribed in Materials and Meth-
ods. The percentage of positive
cells compared with the appro-
priate isotype control (grey histo-
gram) is shown for each antibody.
(B) Macrophages were preincu-
bated with the antibody or tet-
rapeptide shown for 15 min at
48C in the presence of 15% au-
tologous human serum. The PI
in the presence of the inhibitor was calculated from three separate experiments, and results were compared with the serum control by Student’s t test. In-
hibition by antibodies to CR3 (P 5 0.0001), CR4 (P 5 0.0001), annexin V (ANN; P 5 0.001), and RGDS (P 5 0.01) was statistically significant,
whereas neither anti-CR1, anti-CD36, anti-CD14 (61D3 and 63D3), nor the control tetrapeptide (RGES) significantly inhibited uptake in the presence
of serum.
RGDS (which is thought not to inhibit CD11/CD18 [22])
significantly inhibited uptake of apoptotic cells under these
conditions, although specific inhibition (inhibition by
RGDS-RGES) was only 16% (Fig. 4 B).
To definitively test the role of CR3 in the recognition of
apoptotic cells, we examined the ability of a Chinese ham-
ster ovary (CHO) cell line stably transfected with CR3 (23)
to phagocytose apoptotic cells. As shown in Fig. 5 C, the
PI of nontransfected CHO cells was near baseline in the
presence or absence of serum, whereas the CR3-trans-
fected cell line CHO-R3 had a PI approximating that ob-
served in human macrophages in the presence of serum and
showed extensive rosetting (Fig. 5 B).
Discussion
These studies demonstrate for the first time that both the
classical and alternative pathways of complement are acti-
vated by apoptotic cells in isologous conditions leading to
deposition of C3bi on the apoptotic cell surface, that PS is
at least partially involved in this activation, and that recog-
nition of ligand by the macrophage complement receptors
CR3 and CR4 is the most efficient mechanism of uptake
of apoptotic cells in the presence of serum. Since C1q has
been reported to bind to apoptotic cells (24), the results of
our studies suggest that apoptotic cells activate the classical
pathway but that amplification via the alternative pathway
loop (25) is required for efficient recognition by macro-
phages. The requirement for both classical and alternative
complement pathway activation for efficient uptake of au-
tologous apoptotic cells differs from reports of exclusive al-
ternative pathway activation by the transformed cell lines,
Jurkat T lymphocytes (26) and a lung adenocarcinoma (27).
These differences may be explained by the conditions and/
or reagents used. For example, the use of serum with selec-
tive complement component deficiency revealed that com-
plement activation by hemodialysis membranes, long thought
to be mediated exclusively by the alternative pathway, re-
quired initiation by the classical pathway (28). Also, in
studies by Nagasawa and colleagues (26), apoptosis was in-
Figure 3. Autologous apoptotic
cells activate serum complement
and are coated with the C3 break-
down product, C3bi. Lymphocytes
(A–D) or neutrophils (E) were un-
treated (A) or induced to undergo
apoptosis (B–E) and incubated with
15% autologous serum for 1 h as
described in Materials and Meth-
ods. Lymphocytes were stained with PE-conjugated murine anti–human-
C3bi (Quidel; bold line) or PE-IgG2bk as isotype control (dotted line). In
C and D, apoptotic lymphocytes were incubated with 0.4 or 1.6 mM an-
nexin V, respectively (provided by Dr. A.E. Gharavi, Louisiana State
University Medical Center, New Orleans, LA), for 10 min at 48C fol-
lowed by incubation with RPMI containing 15% autologous serum for
1 h/378C/5% CO2, and then stained for C3bi as in A and B. In E, neutro-
phils were induced to undergo apoptosis, incubated with 15% autologous
serum for 1 h, and then analyzed by two-color flow cytometry as shown.
The percent staining in each compartment is shown. These results are
representative of four experiments.2317 Mevorach et al.
duced by antibody (anti-Fas) and a transformed macro-
phage-like cell, THP-1, used for phagocytosis.
During apoptosis, a key alteration to the cell surface
membrane is the translocation of the negatively charged PS
from the inside to the outside of the cell (18, 19). In addi-
tion, it is known that PS exposure on apoptotic cells is re-
quired for efficient uptake of apoptotic cells by phagocytes
(11). To determine whether PS exposure, complement ac-
tivation, and phagocytic recognition of cell-bound comple-
ment products could be sequential steps in a physiological
pathway for removal of apoptotic cells, we first examined
the relationship between PS exposure on the cell mem-
brane and complement activation. Annexin V binds to PS
on the cell surface in a Ca21 dependent manner (17).
Therefore, we examined whether annexin V would com-
pete for complement binding and activation. The z40%
reduction in C3bi deposition on apoptotic cells preincu-
bated with annexin V strongly suggests that exposure of PS
either directly or indirectly activates complement. The de-
tection of C3bi on almost all of the annexin Vhi expressing
cells and the failure of annexin V to completely inhibit
complement activation suggest that the binding sites for
complement and annexin V are overlapping but not identi-
cal and/or that other molecules contribute to complement
activation.
Negatively charged phospholipids such as cardiolipin
have previously been shown to activate C1 in the absence
of antibody (29). Furthermore, clearance of PS-containing
liposomes by the liver is complement dependent (30).
These observations reinforce the findings that PS activates
complement and is required for uptake by fixed macro-
phages. The reason why complement activation on apop-
totic cells fails to cause lysis of the cell is uncertain but may
be explained by modulation of complement regulatory
molecules (31, 32), binding of additional serum proteins on
the surface of apoptotic cells, alteration in the composition
of the cell surface membrane, the rapid removal of op-
sonized cells, or a combination of these factors.
Complement activation and amplification via the alter-
native pathway loop rapidly lead to cleavage of C3 and co-
valent binding of C3b to the activating cell surface. In the
presence of serum, Factor I proteolytically cleaves C3b to
C3bi. Whereas C3b has a half-life of only 90 s, the half-life
of C3bi is z35 min (33), accounting for its major role in
opsonization (34–36). To compare the relative roles of the
macrophage complement receptors that recognize C3bi
(CR3 and CR4) with previously described apoptotic cell
receptor/ligand systems, we analyzed the effect of different
inhibitory mAbs or peptides on the uptake of apoptotic
cells by macrophages in the presence of serum. For human
peripheral blood–derived macrophages, only blockade of
CR3 or CR4 reduced the PI by .50%, whereas blockade
of previously described receptors or ligands had a modest
effect (,20% inhibition). The dominant role of the com-
plement receptors CR3 and CR4 in the uptake of apop-
totic cells in the presence of serum suggests that comple-
ment may play the most active role in removal of apoptotic
cells in vivo (see below). In view of the cross-talk between
integrins (37, 38), it is possible that complement receptor
engagement suppresses or has a transdominant inhibitory
effect on other integrin-containing receptors.
The failure of previous studies to demonstrate a role for
Figure 5. CR3 is responsible for recognition of opsonized apoptotic
cells. CHO cells or CHO cells stably transfected with human CR3 (CHO-
R3; provided by Drs. R.R. Ingalls and D.T. Golenbock, Boston Medical
Center, Boston, MA [23]) were Wright stained and examined for uptake of
apoptotic thymocytes in the absence (A) or presence (B) of serum. Original
magnification: 3400. (C) The results of four experiments using serum defi-
cient in C3 (C3d) or C9 (C9d) are shown.2318 Complement Clearance of Apoptotic Cells
complement receptors in the uptake of apoptotic cells in
vitro is, most likely, explained by the omission of serum in
these assays (39) or aging of neutrophils in the presence of
serum before the phagocytic assay in the absence of serum
(40). In the latter study, complement is likely to have been
activated with the deposition of C3bi on the apoptotic
neutrophil in the “aging” step and thereby may account for
the lack of a requirement for serum in the phagocytosis as-
say. Complement components may also have been secreted
by the macrophages (41) in the 4-h assay period. When ap-
optotic cells were exposed to serum but the phagocytosis
step was performed in the absence of serum, we also ob-
served that the PI was increased more than threefold. The
slightly lower PI in the two step assay compared with the
one step assay could be explained by increased proteolysis
of C3bi by serum factors such as Factor I, or may indicate that
other serum factors are required for optimal phagocytosis.
CR3 and CR4 have interesting relationships with previ-
ously described phagocytic receptors for apoptotic cells.
The CD14 binding sites for apoptotic cells and LPS on hu-
man macrophages are identical or very close (9). Since
CR3 and CR4 (42) also bind to LPS/LPS-binding protein,
these receptors may have a similar hydrophobic lipid bind-
ing site or CD14, a glycosylphosphatidyl inositol (GPI)-
linked membrane protein, may associate with the exodomains
of the complement receptors to promote phagocytosis and/
or signal transduction (43) after exposure to apoptotic cells.
Another recently described protein proposed to be in-
volved in the engulfment of cell corpses is the C. elegans
protein CED-5 (the mammalian and Drosophila melanogaster
homologues are DOCK 180 and Myoblast city, respec-
tively [44]). Interestingly, DOCK 180 interacts with CRK,
a protein that regulates integrin-mediated ras signal trans-
duction (for a review, see reference 45). Taken together
with the results reported here, these findings suggest a pos-
sible relationship between engagement of the two integrins
and activation of apoptotic cell engulfment.
The requirement for complement activation in the effi-
cient uptake of autologous apoptotic cells appears contrary
to the notion that phagocytosis of apoptotic cells is a non-
inflammatory process (46). However, binding and phago-
cytosis via macrophage CR3 do not trigger leukotriene re-
lease (47) or a respiratory burst (48, 49). Furthermore,
ligation of CR3 and other complement receptors may ac-
tually be immunosuppressive by downregulating IL-12 and
IFN-g production by human monocytes (50–52). There-
fore, it seems likely that the pro- or antiinflammatory con-
sequences of complement activation on macrophages de-
pends on the specific ligands encountered and receptors
engaged (see below).
During the normal turnover of lymphocytes and my-
eloid cells, billions of apoptotic cells need to be eliminated
daily within the circulation (53). The results of these stud-
ies suggest an important homeostatic role for complement
in the noninflammatory clearance of apoptotic cells. Since
complement activation is required for efficient phagocytic
uptake of apoptotic cells by macrophages as shown here,
deficiencies in the early components of the complement
pathway would be predicted to result in impaired clearance
of apoptotic cells. We have recently shown that exposure
to excess numbers of apoptotic cells can induce autoanti-
body production and glomerular IgG deposition in normal
mice (16), and Botto et al. (54) detected abnormal numbers
of apoptotic cells in the kidneys of mice deficient in C1q
that develop a lupus-like disease. Taken together, these
findings provide a compelling role for complement in the
clearance of apoptotic cells in vivo and could explain why
humans with early complement component deficiencies
develop SLE. In contrast to patients with defective expres-
sion of the common b chain (CD18) who develop recur-
rent bacterial infections (22), a patient with a selective defi-
ciency of CD11b epitope 17 expression presented with
SLE (55). However, it is unlikely that lack of CD11b alone
is sufficient to develop lupus, as CD11b-deficient mice are
clinically well (56) and our in vitro studies indicate that
both CR3 and CR4 are involved in uptake of apoptotic
cells. In addition, apoptotic cell death could also explain
why complement is activated in diverse pathologies such as
myocardial infarctions, burns, AIDS, and UV irradiation,
where significant numbers of apoptotic cells are produced
(57–60).
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